ArticleNature biotechnology2022
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR.
Open access · bronzeAbstract read
In one paragraph
Article in Nature biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- The Impact of Severe Albuminuria on the Proinflammatory Monocyte Subset CD14++CD16+ and Antigen-Specific Immune Responses.International journal of molecular sciences · 2026Article
- Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Review
- A safe, T cell-inducing heterologous vaccine against elephant endotheliotropic herpesvirus in a proof-of-concept study.Nature communications · 2025Article
- Raman Spectroscopy Can Identify Acute and Persistent Biochemical Changes in Leukocytes From Patients With COVID-19 and Non-COVID-19-Associated Sepsis.Biotechnology journal · 2025Article
- Article
- Article
- Comparison of different T cell assays for the retrospective determination of SARS-CoV-2 infection.The Journal of general virology · 2024Article
- Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India.Scientific reports · 2024Article
- Article
- A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation.NPJ vaccines · 2024Article
- Neutralizing antibody levels detected early after mRNA-based vaccination do not predict by themselves subsequent breakthrough infections of SARS-CoV-2.Frontiers in immunology · 2024Article
- Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection.Vaccines · 2023Review
- Performance of T-TrackDiagnostics (Basel, Switzerland) · 2023Article
- Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.The Journal of clinical investigation · 2023Article
- Constructing a full, multiple-layer interactome for SARS-CoV-2 in the context of lung disease: Linking the virus with human genes and microbes.PLoS computational biology · 2023Article
- Can T Cells Abort SARS-CoV-2 and Other Viral Infections?International journal of molecular sciences · 2023Review
- Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development.Frontiers in immunology · 2023Review
- Review
- SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.Microbiology spectrum · 2022Article
- Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors at 13 institutions in 4 countries.
Megan SchwarzDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Denis TorreDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniel Lozano-OjalvoPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3524-2929
Anthony T TanProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
Tommaso TabaglioInstitute of Molecular and Cell Biology, IMCB, A*STAR, Singapore, Singapore.ORCID http://orcid.org/0000-0001-6873-3073
Slim MzoughiDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rodrigo Sanchez-TarjueloDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nina Le BertProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.ORCID http://orcid.org/0000-0003-0502-2527
Joey Ming Er LimProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
Sandra HatemDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kevin TuballesPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-5899-7080
Carmen CamaraDepartment of Immunology, University Hospital La Paz-IdiPAZ, Madrid, Spain.
Eduardo Lopez-GranadosDepartment of Immunology, University Hospital La Paz-IdiPAZ, Madrid, Spain.
Estela Paz-ArtalDepartment of Immunology, Research Institution, Sanitaria Hospital, Madrid, Spain.
Rafael Correa-RochaLaboratory of Immune-Regulation, Research Institute Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.ORCID http://orcid.org/0000-0003-3456-9986
Alberto OrtizDepartment of Nephrology, IIS-Fundación Jimenez Díaz, Madrid, Spain.ORCID http://orcid.org/0000-0002-9805-9523
Marcos Lopez-HoyosDepartment of Immunology, Hospital University of Marqués de Valdecilla-IDIVAL, Santander, Spain.
Jose PortolesDepartment of Nephrology, Hospital of Puerta de Hierro, Madrid, Spain.ORCID http://orcid.org/0000-0002-2114-1385
Isabel CerveraNational Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
Maria Gonzalez-PerezNational Center for Microbiology, Carlos III Health Institute, Madrid, Spain.ORCID http://orcid.org/0000-0003-0838-4734
Irene Bodega-MayorNational Center for Microbiology, Carlos III Health Institute, Madrid, Spain.ORCID http://orcid.org/0000-0002-4756-8889
Patricia CondeNational Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
Jesús Oteo-IglesiasNational Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
Alberto M BorobiaClinical Pharmacology, University Hospital La Paz-IDIPAZ, Platform of Clinical Research Units and Clinical Trials, Spain Faculty of Medicine Autonomous University of Madrid, Madrid, Spain.
Antonio J CarcasClinical Pharmacology, University Hospital La Paz-IDIPAZ, Platform of Clinical Research Units and Clinical Trials, Spain Faculty of Medicine Autonomous University of Madrid, Madrid, Spain.
Jesús FríasClinical Pharmacology, University Hospital La Paz-IDIPAZ, Platform of Clinical Research Units and Clinical Trials, Spain Faculty of Medicine Autonomous University of Madrid, Madrid, Spain.
Cristóbal Belda-IniestaCarlos III Health Institute, Madrid, Spain.
Jessica S Y HoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-2234-2602
Kemuel NunezDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Saboor HekmatyDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-9964-5797
Kevin MohammedDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
William M MarsigliaDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Arvin C DarDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0318-4848
Cecilia BerinDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Giuseppe NicolettiHyris Limited, London, UK.
Isabella Della NoceHyris Limited, London, UK.
Lorenzo ColomboHyris Limited, London, UK.
Cristina LapucciGenetic Unit, Synlab Italia, Castenedolo, Italy.
Graziano SantoroGenetic Unit, Synlab Italia, Castenedolo, Italy.ORCID http://orcid.org/0000-0002-6459-5846
Maurizio FerrariIRCCS, SDN, Napoli, Italy.
Kai NiePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Manishkumar PatelPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-7949-5610
Vanessa BarcessatPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-0256-2862
Sacha GnjaticDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5643-9520
Jocelyn HarrisPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert SebraDepartment of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Miriam MeradPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-4481-7827
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4121-776X
Seunghee Kim-SchulzePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ivan MarazziDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-3376-0922
Antonio BertolettiProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore. antonio@duke-nus.edu.sg.ORCID http://orcid.org/0000-0002-2942-0485
Jordi OchandoDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jordi.ochando@mssm.edu.ORCID http://orcid.org/0000-0001-7037-1681
Ernesto GuccioneDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ernesto.guccione@mssm.edu.ORCID http://orcid.org/0000-0001-7764-5307
Icahn School of Medicine at Mount Sinai · USInstituto de Salud Carlos III · ESDuke-NUS Medical School · SGHospital La Paz Institute for Health Research · ESSynesis · ITAgency for Science, Technology and Research · SGHospital General Universitario Gregorio Marañón · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario Puerta de Hierro Majadahonda · ESMarqués de Valdecilla University Hospital · ESSDN Istituto di Ricerca Diagnostica e Nucleare · ITSema4 (United States) · USUniversidad Complutense de Madrid · ES
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MTRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6MCharacterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9MDefining the relationship between kinase inhibitor pharmacophores and pro-/anti-targets using in vivo models of colorectal cancerK00CA212474 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MARSIGLIA, WILLIAM M · 2019 to 2022
$374kNCI NIH HHS K00 CA212474NCI NIH HHS P30 CA196521NCI NIH HHS T32 CA078207NCI NIH HHS U24 CA224319NIDDK NIH HHS U01 DK124165
Abstract
Fast, high-throughput methods for measuring the level and duration of protective immune responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here we report the development of two quantitative PCR assays for SARS-CoV-2-specific T cell activation. The assays are rapid, internally normalized and probe-based: qTACT requires RNA extraction and dqTACT avoids sample preparation steps. Both assays rely on the quantification of CXCL10 messenger RNA, a chemokine whose expression is strongly correlated with activation of antigen-specific T cells. On restimulation of whole-blood cells with SARS-CoV-2 viral antigens, viral-specific T cells secrete IFN-γ, which stimulates monocytes to produce CXCL10. CXCL10 mRNA can thus serve as a proxy to quantify cellular immunity. Our assays may allow large-scale monitoring of the magnitude and duration of functional T cell immunity to SARS-CoV-2, thus helping to prioritize revaccination strategies in vulnerable populations.
Indexed as
COVID-19SARS-CoV-2HumansImmunity, CellularPolymerase Chain ReactionT-Lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.